Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mushroom-OCD: Psilocybin for Obsessive-Compulsive Disorder
NCT07347405Phase 1Recruiting
- Sponsor
- Francisco A. Moreno
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in obsessive compulsive disorder (OCD) (3 arms), sponsored by Francisco A. Moreno. Primary endpoints: Yale Brown Obsessive Compulsive Scale, Adverse Events and 1 more. Started May 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT07347405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347405.